Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar

Elias Tayar a,1, Sami Abdeen a,1, Muna Abed Alah a,1, Hiam Chemaitelly b,c,d, Iheb Bougmiza e,f, Houssein H. Ayoub g, Anvar Hassan Kaleeckal h, Ali Nizar Latif h, Riyazuddin Mohammad Shaik h, Hamad Eid Al-Romaihi i, Mohamed H. Al-Thani i, Roberto Bertollini i, Laith J. Abu-Raddad b,c,d,i, Abdullatif Al-Khal k

a Community Medicine Department, Hamad Medical Corporation, Doha, Qatar
b Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar
c World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar
d Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA
e Community Medicine Department, Primary Health Care Corporation, Doha, Qatar
f Community Medicine Department, College of Medicine, Sousse University, Tunisia
g Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar
h Business Intelligence and Operational Performance Unit, Hamad Medical Corporation, Doha, Qatar
i Ministry of Public Health, Doha, Qatar
j Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar
k Medical Education Department, Hamad Medical Corporation, Doha, Qatar

A R T I C L E   I N F O
Article history:
Received 18 July 2022
Received in revised form 17 December 2022
Accepted 22 December 2022

Keywords:
Influenza
COVID-19
Vaccine
Case-control
Immunology
Epidemiology

A B S T R A C T
Background: Some studies have reported that influenza vaccination is associated with lower risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or coronavirus disease 2019 (COVID-19) morbidity and mortality. This study aims to estimate effectiveness of influenza vaccination, using Abbott’s quadrivalent Influvac Tetra vaccine, against SARS-CoV-2 infection and against severe COVID-19.

Methods: This matched, test-negative, case-control study was implemented on a population of 30,774 healthcare workers (HCWs) in Qatar during the 2020 annual influenza vaccination campaign, September 17, 2020–December 31, 2020, before introduction of COVID-19 vaccination.

Results: Of 30,774 HCWs, 576 with PCR-positive tests and 10,033 with exclusively PCR-negative tests were eligible for inclusion in the study. Matching by sex, age, nationality, reason for PCR testing, and PCR test date yielded 518 cases matched to 2058 controls. Median duration between influenza vaccination and the PCR test was 43 days (IQR, 29–62). Estimated effectiveness of influenza vaccination against SARS-CoV-2 infection > 14 days after receiving the vaccine was 29.7% (95% CI: 5.5–47.7%). Estimated effectiveness of influenza vaccination against severe, critical, or fatal COVID-19 was 88.9% (95% CI: 41.9–98.7%). Sensitivity analyses confirmed the main analysis results.

Conclusions: Recent influenza vaccination is associated with a significant reduction in the risk of SARS-CoV-2 infection and COVID-19 severity.
© 2022 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

https://doi.org/10.1016/j.jiph.2022.12.016
1876-0341© 2022 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

* These authors contributed equally.
Introduction

Influenza vaccination protects against influenza infection and reduces morbidity and mortality of seasonal influenza [1]. This vaccination is strongly recommended for high-risk groups such as elderly persons and healthcare workers (HCWs) [2]. A number of studies have reported that influenza vaccination is also associated with lower risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or coronavirus disease 2019 (COVID-19) morbidity and mortality [3–13]. However, reported apparent protection against SARS-CoV-2 infection and severe COVID-19 could have arisen due to bias and may not have reflected a genuine biological effect. In particular, this protection may have been due to the healthy user effect [14], whereby health-aware persons are more likely to receive an influenza vaccine, and simultaneously, to practice health behaviors that reduce their risk of acquiring the infection [3,5].

Against this background, we assessed effectiveness of vaccination with Abbott’s quadrivalent Influvac Tetra vaccine against SARS-CoV-2 infection, as documented using polymerase chain reaction (PCR) testing. Effectiveness of influenza vaccination was also assessed against infection progression to severe (acute-care hospitalization) [15], critical (intensive-care-unit hospitalization) [15], or fatal [16] COVID-19 disease, per World Health Organization definitions [15,16]. Both of these effectiveness measures were assessed among HCWs in Qatar during the 2020 annual influenza vaccination campaign, and before introduction of COVID-19 vaccination. Since variation in health behaviors among HCWs is presumably less than that among the general population, conducting this study among HCWs allowed us to minimize the influence of the healthy user effect on effectiveness estimates.

Materials and methods

Study design

This study was retrospective and conducted among HCWs at Hamad Medical Corporation, the principal provider of public healthcare services in Qatar and the nationally designated entity for COVID-19-related healthcare needs. The study analyzed the centralized, national, federated databases for COVID-19 laboratory testing, vaccination, hospitalization, and death, retrieved from the integrated nationwide digital-health information platform. These databases include all SARS-CoV-2-related data and associated demographic information, with no missing information, since the pandemic onset, documenting all PCR tests. Influenza vaccination data were retrieved from Hamad Medical Corporation’s influenza vaccination database. Further descriptions of these databases have been reported previously [17–23].

SARS-CoV-2 testing in the healthcare system in Qatar was done at a mass scale, and mostly for routine reasons [18,24]. Most infections were diagnosed due to routine testing rather than because of symptoms [18]. Every PCR test conducted in Qatar, regardless of location or setting, was tracked nationally and was classified based on symptoms present at the time of testing and the reason for testing (clinical symptoms, contact tracing, surveys or random testing campaigns, individual requests, routine healthcare testing, pre-travel, screening at ports of entry, or other). All PCR testing done during the present study was factored in the analyses of this study. Qatar has unusually young, diverse demographics, in that only 9% of its residents are ≥ 50 years of age, and 89% are expatriates from over 150 countries [17]. This diversity also characterizes the HCW population.

Effectiveness of influenza vaccination against SARS-CoV-2 infection was assessed using the test-negative, case-control study design, a preferred design for assessing vaccine effectiveness against influenza [25,26]. This design was also validated in Qatar’s population and has been repeatedly applied in previous studies in this country to assess COVID-19 vaccine effectiveness [18,20,21,24,27–29].

SARS-CoV-2 PCR testing and vaccination records were retrieved for all HCWs at HMC. Any HCW with a SARS-CoV-2 PCR test performed between September 17, 2020 and December 31, 2020 was eligible for inclusion in the study. This duration coincided with the national annual influenza vaccination campaign that typically starts in September or October, and continues for several months thereafter. Influenza vaccination is offered free of charge to all citizens and residents and is offered in both public and private healthcare institutions. During the 2020 influenza vaccination campaign, only Abbott’s quadrivalent Influvac Tetra vaccine was used in the national influenza vaccination campaign. Individuals who did not receive this influenza vaccine are unlikely to have received any other influenza vaccine.

The study was concluded at the start of the mass COVID-19 vaccination campaign to ensure that the estimated effectiveness of the influenza vaccine does not factor any protective effect for SARS-CoV-2 vaccination. During the study, SARS-CoV-2 incidence was due to the original SARS-CoV-2 virus, before introduction of SARS-CoV-2 variants of concern [30–34]. SARS-CoV-2 incidence was also relatively low during the study with no wave materializing during this time [33,35].

To estimate effectiveness against SARS-CoV-2 infection, we exact-matched cases (HCWs with PCR-positive tests) and controls (HCWs with PCR-negative tests) identified during the study in a 1:5 ratio by sex, 10-year age groups, 10-nationality groups, reason for PCR testing, and bi-weekly PCR test date, to control for known differences in SARS-CoV-2 exposure risk in Qatar [17,35–38]. Matching by these factors was shown previously in studies of different epidemiologic designs to provide adequate control of differences in the risk of exposure to SARS-CoV-2 infection in Qatar [18,21,23,29,39].

Only the first PCR-positive test for cases and the first PCR-negative test for controls during the study were included in the present analysis. Controls included individuals with no record of a PCR-positive test during the study period. HCWs with a PCR test within 14 days after receiving the influenza vaccine and those who received COVID-19 vaccination were excluded. These inclusion and exclusion criteria were implemented to allow adequate time for build-up of immunity after vaccination [20], and to minimize different types of potential bias, as informed by earlier analyses on the same population [18,29]. Every control that met the inclusion criteria and that could be matched to a case was included in the analysis.

Classification of COVID-19 case severity [15], criticality [15], and fatality [16] followed World Health Organization guidelines, and assessments were made by trained medical personnel using individual chart reviews, as part of a national protocol applied to every hospitalized COVID-19 patient. Details of COVID-19 severity, criticality, and fatality classifications are found in Supplementary Section 1.

Every hospitalized COVID-19 patient underwent infection severity assessment every three days until discharge or death. We classified individuals who progressed to severe, critical, or fatal COVID-19 between the time of the PCR-positive test and the end of the study based on their worst disease outcome, starting with death [16], followed by critical disease [15], and then severe disease [15]. Individuals with a PCR-documented infection, but no COVID-19 hospitalization record, were assumed to have a SARS-CoV-2 infection that did not progress to severe, critical, or fatal COVID-19, that is asymptomatic, mild or moderate COVID-19.

Laboratory methods

Details of laboratory methods for real-time reverse-transcription PCR (RT-qPCR) testing are found in Supplementary Section 2. All PCR testing was conducted at the Hamad Medical Corporation Central
Laboratory or at Sidra Medicine Laboratory, following standardized protocols.

Statistical analysis

Baseline characteristics of cases and controls were reported using descriptive statistics. Groups were compared using standardized mean differences (SMDs), with SMD below or close to 0.1 indicating adequate matching [40]. Conditional logistic regression factoring the matched design was performed to compare odds of influenza vaccination in cases versus controls. This analytical approach, including matching by bi-weekly PCR test date, minimizes potential bias due to variation in epidemic phase [25,41] and roll-out of vaccination during the study [25,41]. Interactions were not considered. The resulting estimates for the adjusted odds ratio and 95% confidence interval (CI) were then used to estimate influenza vaccination effectiveness and corresponding 95% CI using the equation [25,26]:

\[ \text{Effectiveness} = 1 - \text{odds ratio of influenza vaccination among cases versus controls} \]

Effectiveness was estimated against SARS-CoV-2 infection, whether symptomatic or asymptomatic, and against any severe, critical, or fatal COVID-19. Sensitivity analyses were conducted to investigate the impact of adjusting for prior SARS-CoV-2 infection in the conditional logistic regression, and of modifying the study inclusion and exclusion criteria on the estimate of influenza vaccination effectiveness. The latter was informed by an established analysis plan to investigate sources of potential bias [18,29], and encompassed exclusion of individuals with prior SARS-CoV-2 infection, exclusion of travel-related PCR testing, or inclusion of all PCR-positive and PCR-negative tests for cases and controls. Statistical analyses were conducted using STATA/SE version 17.0 (Stata Corporation, College Station, TX, USA).

Oversight

Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards approved this retrospective study with a waiver of informed consent. The research was performed in accordance with relevant guidelines and regulations and in accordance with the Declaration of Helsinki [42]. The study was reported following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. The STROBE checklist can be found in Supplementary Table 1.

Results

Fig. 1 shows the process of selecting the study population. Of 30,774 HCWs at Hamad Medical Corporation, only 12,015 individuals who had one or more SARS-CoV-2 PCR tests between September 17, 2020 and December 31, 2020 (study was designed to end before the start of COVID-19 mass vaccination campaigns) qualified for further investigation in this study. Of these, 576 HCWs with a PCR-positive test and 10,033 with exclusively PCR-negative tests met the study inclusion criteria. Exact-matching in a 1:5 ratio yielded 518 cases matched to 2058 controls that were included in the analysis.

Table 1 describes characteristics of cases and controls. The median age was 36 years (interquartile range (IQR), 32–44) for cases and 35 years (IQR, 32–42) for controls in the matched samples. Slightly less than half (~46%) of cases and controls were males. Study participants were HCWs residing in Qatar, but of diverse nationalities. There were 31 different nationalities among matched cases and 47 different nationalities among matched controls (Table 1).

Nearly two-thirds of study participants were tested because of COVID-like symptoms. Matched study groups were well balanced across matching factors. Among matched cases and controls, respectively, 49.0% versus 53.4% had 0 comorbidities, 27.4% versus
Recent influenza vaccination was associated with a 30% reduction in the risk of SARS-CoV-2 infection by the original virus, before introduction of variants of concern. Recent influenza vaccination was

Table 1
Characteristics of cases (healthcare workers with PCR-positive tests) and controls (healthcare workers with PCR-negative tests).

| Characteristics | All cases and controls (unmatched) | Matched cases and controls* |
|-----------------|------------------------------------|----------------------------|
|                 | Cases (PCR-confirmed infection) | Controls (PCR-negative) | SMDb | Cases (PCR-confirmed infection) | Controls (PCR-negative) | SMDb |
| No              | 57%  | 10,033           | 36 (32–44) | 0.04c | 518   | 2058           | 35 (32–42) | 0.11c |
| Age group – no. (%) |                     |                         |                |                |                         |                |                |
| < 30 years      | 80 (13.9) | 1370 (13.7) | 0.13            | 65 (12.6) | 233 (11.3) | 0.18 |
| 30–39 years     | 261 (45.3) | 4973 (45.6) | 253 (49.2) | 1152 (56.0) |                |                |
| 40–49 years     | 145 (25.2) | 2354 (21.5) | 128 (24.7) | 496 (24.1) |                |                |
| 50–59 years     | 81 (14.1)  | 1120 (11.2) | 66 (12.7)  | 171 (8.3)  |                |                |
| 60–69 years     | 9 (1.6)    | 201 (2.0)   | 4 (0.8)    | 6 (0.3)    |                |                |
| 70 + years      | 0 (0.0)    | 15 (0.2)    | –          | –         |                |                |
| Sex             |                      |                         |                |                |                      |                |
| Male            | 270 (46.9) | 4949 (49.3) | 0.05          | 243 (46.9) | 951 (46.2) | 0.01 |
| Female          | 306 (53.1) | 5084 (50.7) | 275 (53.1) | 1107 (53.8) |                |                |
| Nationalityd    |                      |                         |                |                |                      |                |
| Bangladeshi     | 1 (0.2)    | 77 (0.8)    | 0.15            | –          | –         | 0.15 |
| Egyptian        | 30 (5.2)   | 510 (5.1)   | 21 (4.1) | 62 (3.0) |                |                |
| Indian          | 196 (34.0) | 3095 (30.9) | 185 (35.7) | 814 (39.6) |                |                |
| Nepalese        | 6 (1.0)    | 45 (0.5)    | 1 (0.2)    | 4 (0.2)    |                |                |
| Pakistani       | 11 (1.9)   | 223 (2.2)   | 6 (1.2)    | 11 (0.5)   |                |                |
| Qatari          | 78 (13.5)  | 1412 (14.1) | 74 (14.3) | 262 (12.7) |                |                |
| Sri Lankan      | 1 (0.2)    | 22 (0.2)    | –          | –         |                |                |
| Sudanese        | 24 (4.2)   | 347 (3.5)   | 18 (3.5)   | 43 (2.1)   |                |                |
| Other nationalitiesd | 151 (26.2) | 2665 (26.6) | 141 (27.2) | 591 (28.7) |                |                |
| Reason for PCR testing |                      |                         |                |                |                      |                |
| Clinical suspicion | 320 (55.6) | 3680 (36.7) | 0.57          | 299 (57.7) | 1264 (61.4) | 0.14 |
| Contact tracing  | 105 (18.2) | 1197 (11.9) | 95 (18.3)  | 346 (16.8) |                |                |
| Other testing    | 13 (2.3)   | 399 (4.0)   | 10 (1.9)   | 21 (1.0)   |                |                |
| Port of entry    | 52 (9.0)   | 1359 (13.6) | 43 (8.3)   | 172 (8.4)  |                |                |
| Individual request | 18 (3.1)   | 535 (5.3)   | 31 (2.1)   | 19 (0.9)   |                |                |
| Survey testing   | 37 (6.4)   | 1081 (10.8) | 32 (6.2)   | 128 (6.2)  |                |                |
| Health care routine testing | 30 (5.2)   | 1517 (15.1) | 27 (5.2)   | 103 (5.0)  |                |                |
| Pre-travel       | 1 (0.2)    | 265 (2.6)   | 1 (0.2)    | 5 (0.2)    |                |                |
| Comorbidity count |                      |                         |                |                |                      |                |
| 0               | 276 (47.9) | 5295 (52.8) | 0.11          | 254 (49.0) | 1099 (53.4) | 0.10 |
| 1               | 157 (27.3) | 2603 (25.9) | 142 (27.4) | 544 (26.4) |                |                |
| 2               | 82 (14.2)  | 1175 (11.7) | 70 (13.5)  | 251 (12.2) |                |                |
| ≥ 3             | 61 (10.6)  | 960 (9.6)   | 52 (10.0)  | 164 (8.0)  |                |                |
| COVID-19 severity |                      |                         |                |                |                      |                |
| Asymptomatic, mild, or moderate COVID-19 | 551 (95.7) | –         | 498 (96.1) |                |                |
| Severe COVID-19  | 23 (4.0)   | –          | 18 (3.5)   | –         |                |                |
| Critical COVID-19 | 2 (0.3)    | –          | 2 (0.4)    | –         |                |                |
| Fatal COVID-19   | 0          | –          | 0          | –         |                |                |

Abbreviations: IQR = interquartile range; PCR = polymerase chain reaction; SMD = standardized mean difference.

*Cases and controls were exact-matched in a 1:5 ratio by sex, 10-year age group, 10 nationality groups, reason for PCR testing, and bi-weekly PCR test date.

**SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation.

Three nationalities were chosen to represent the most numerous groups in the population of Qatar.

†There were 22 other nationalities in the total case population, 74 other nationalities in the total control population, 22 other nationalities among matched cases, and 38 other nationalities among matched controls. Matched cases included the following “other nationalities”: American, Australian, British, Canadian, Djiboutian, Eritrean, Ethiopian, German, Iranian, Iraqi, Irish, Jordanian, Lebanese, Libyan, Mauritian, Moroccan, New Zealander, Nigerian, Omani, Palestinian, Saudi, Serbian, Somali, South African, Syrian, Tanzanian, Tunisian, Turkish, and Yemeni.

26.4% had 1 comorbidity, 13.5% versus 12.2% had 2 comorbidities, and 10.0% versus 8.0% had ≥ 3 comorbidities, with an SMD of 0.10 indicating adequate balance. The median duration between influenza vaccination and the PCR test was 43 days (IQR, 29–62).

The odds of having a record of influenza vaccination among PCR-positive cases compared to PCR-negative controls was 0.70 (95% CI: 0.52–0.95), indicating lower frequency of vaccination among cases compared to controls. Accordingly, the estimated effectiveness of influenza vaccination against SARS-CoV-2 infection > 14 days after receiving the vaccine was 29.7% (95% CI: 5.5–47.7%). All sensitivity analyses yielded consistent results, confirming main analysis results (Table 2).

Table 2 describes characteristics of vaccinated and unvaccinated matched PCR-positive cases. Of 127 matched PCR-positive cases who received influenza vaccination, only 1 progressed to severe disease, but none to critical or fatal COVID-19 (Fig. 1). Meanwhile, of the 391 matched PCR-positive cases who did not receive influenza vaccination, 17 progressed to severe, 2 to critical, but none to fatal COVID-19. The odds of having a record of influenza vaccination among severe, critical, or fatal COVID-19 cases compared to PCR-negative controls was 0.11 (95% CI: 0.01–0.96), indicating lower frequency of vaccination among cases compared to controls. Accordingly, the estimated effectiveness of influenza vaccination against any severe, critical, or fatal COVID-19 was 88.9% (95% CI: 4.1–98.7% ; Table 2).

Discussion
Recent influenza vaccination was associated with a 30% reduction in the risk of SARS-CoV-2 infection by the original virus, before introduction of variants of concern. Recent influenza vaccination was
The frequency of severe COVID-19 was rare among those vaccinated, with only one case of severe COVID-19 documented among them. These results for a HCW population in which the healthy user effect is perhaps minimized, support the conclusion that recent influenza vaccination has a genuine biological effect in protecting against SARS-CoV-2 infection and COVID-19 severity. These findings are consistent with findings of a systematic review conducted across 36 studies on nearly 56 million individuals [43]. The systematic review estimated the odds ratio comparing individuals with influenza vaccination to those without at 0.80 (95% CI: 0.73–0.87) against SARS-CoV-2 infection, 0.83 (95% CI: 0.72–0.96) against hospitalization in intensive care unit, 0.69 (95% CI: 0.57–0.84) against hospitalization for ventilator support, and 0.69 (95% CI: 0.52–0.93) against fatal COVID-19 [43].

The findings also corroborate findings of studies that found similar protective effects for influenza vaccination [3–13], though other studies did not [44,45]. These findings, as informed by basic science laboratory investigations, may be explained by influenza vaccination triggering nonspecific immune activation, or trained or bystander immunity that is protective against SARS-CoV-2 infection [3–5, 7, 46–51]. Further investigations are warranted to elucidate the exact mechanisms underlying the protective effect of influenza vaccination against COVID-19.

This study has limitations. Effectiveness of only recent influenza vaccination was investigated. The study used a retrospective design that analyzed available routinely collected data as opposed to a longitudinal study design where cohorts are recruited and followed over time. The analysis did not factor influenza vaccination from prior seasons. However, given that nonspecific immune activation may not last beyond few weeks, and in the context of the relatively rapid waning of COVID-19 vaccine immunity [18, 28, 29, 52–54], the observed effectiveness of influenza vaccination is likely short lived. Data were not available on vaccines for other infections (other than influenza and COVID-19 vaccines). However, there is no reason to believe that vaccination against any other infection could have differentially affected the matched cases and controls to affect our results.

Matching was done for sex, age, nationality, reason for PCR testing, and bi-weekly PCR test date, but it was not possible for other factors such as comorbidities, body mass index, use of immunosuppressive drugs and tonics such as zinc and vitamins, which were not available to the authors. However, matching factors used in this study successfully controlled bias in our earlier studies [18, 21, 23, 29, 39]. Nonetheless, one cannot exclude the possibility that in real-world data, bias could arise in unexpected ways, or from

### Table 2

| Analyses                        | Cases | Controls | Adjusted odds ratio (95% CI) | Effectiveness in % (95% CI) |
|---------------------------------|-------|----------|-------------------------------|-----------------------------|
| **Main analysis—Effectiveness against SARS-CoV-2 infection** |       |          |                              |                             |
| Sensitivity analyses            | 127   | 391      | 0.70 (0.52–0.95)              | 29.7 (5.5–47.7)             |
| Adjusting for prior infection in the conditional logistic regression | 126   | 385      | 0.71 (0.53–0.96)              | 28.6 (4.0–46.9)             |
| Excluding prior infection       | 126   | 385      | 0.72 (0.54–0.96)              | 28.1 (3.7–46.3)             |
| Excluding travel-related PCR testing | 124   | 357      | 0.72 (0.54–0.97)              | 27.9 (3.2–46.3)             |
| Including all PCR positive and PCR negative tests | 169   | 494      | 0.66 (0.52–0.85)              | 31.6 (15.0–48.2)            |
| **Severity analysis—Effectiveness against any severe, critical, or fatal COVID-19** | 1     | 19       | 0.11 (0.01–0.96)              | 88.9 (4.1–98.7)             |

### Table 3

| Characteristics | Vaccinated | Unvaccinated | Effectiveness in % (95% CI) | Other nationalities |
|-----------------|------------|--------------|----------------------------|---------------------|
| No              | 127        | 391          | 29.7 (5.5–47.7)             |                    |
| Median age (IQR) | 36 (32–45) | 36 (32–44)   |                             |                    |
| Age group — no. (%) |        |              |                             |                    |
| < 30 years      | 9 (7.1)    | 56 (14.3)    |                             |                    |
| 30–39 years     | 64 (50.4)  | 191 (48.9)   |                             |                    |
| 40–49 years     | 37 (29.1)  | 91 (23.3)    |                             |                    |
| 50–59 years     | 16 (12.6)  | 50 (12.8)    |                             |                    |
| 60–69 years     | 1 (0.8)    | 3 (0.8)      |                             |                    |
| 70 + years      | 0 (0.0)    | 0 (0.0)      |                             |                    |
| Sex             |            |              |                             |                    |
| Male            | 67 (52.8)  | 176 (45.0)   |                             |                    |
| Female          | 60 (47.2)  | 215 (55.0)   |                             |                    |
| Nationality     |            |              |                             |                    |
| Bangladeshi     | 3 (2.4)    | 18 (4.6)     |                             |                    |
| Egyptian        | 30 (23.6)  | 42 (10.7)    |                             |                    |
| Filipino        | 64 (50.4)  | 121 (31.0)   |                             |                    |
| Indian          | 0 (0.0)    | 1 (0.3)      |                             |                    |
| Nepalese        | 1 (0.8)    | 5 (1.3)      |                             |                    |
| Pakistani       | 3 (2.4)    | 71 (18.2)    |                             |                    |
| Qatari          | 2 (1.6)    | 16 (4.1)     |                             |                    |
| Sri Lankan      | 24 (18.9)  | 117 (29.9)   |                             |                    |
| Sudanese        | 3 (2.4)    | 18 (4.6)     |                             |                    |
| Other nationalities | 30 (23.6)  | 42 (10.7)    |                             |                    |
| Reason for PCR testing |        |              |                             |                    |
| Clinical suspicion | 89 (70.1)  | 210 (53.7)   |                             |                    |
| Contact tracing  | 15 (11.8)  | 80 (20.5)    |                             |                    |
| Other survey testing | 3 (2.4)    | 7 (1.8)      |                             |                    |
| Port of entry   | 4 (3.2)    | 39 (10.0)    |                             |                    |
| Individual request | 0 (0.0)    | 11 (2.8)     |                             |                    |
| Survey testing  | 7 (5.5)    | 25 (6.4)     |                             |                    |
| Health care routine testing | 8 (6.3)    | 19 (4.9)     |                             |                    |
| Pre-travel      | 1 (0.8)    | 0 (0.0)      |                             |                    |

Abbreviations: CI = confidence interval; COVID-19 = coronavirus disease 2019; PCR = polymerase chain reaction.

*Cases and controls were exact-matched on a 1:5 ratio by sex, 10-year age group, 10 nationality groups, reason for PCR testing, and bi-weekly PCR test date.

**Vaccine effectiveness was estimated using the test-negative, case-control study design [25,26].**

**Severity [15], criticality [15], and fatality [16] were defined as per World Health Organization guidelines.**

Abbreviations: IQR = interquartile range; PCR = polymerase chain reaction.

*Nationalities were chosen to represent the most populous nationalities in the population of Qatar.

There were 10 other nationalities in the vaccinated group and 20 other nationalities in the unvaccinated group. Vaccinated cases included the following “other nationalities”: Australian, British, Eritrean, Iranian, Iraqi, Jordanian, Palestinian, Somali, Syrian, and Tunisian. Unvaccinated cases included the following “other nationalities”: American, British, Canadian, Djiboutian, Ethiopian, German, Iranian, Iraqi, Irish, Jordanian, Lebanese, Nigerian, Omani, Palestinian, Slovenian, Somali, South African, Syrian, Tunisian, and Yemeni.
unknown sources, such as subtle differences or changes in test-seeking behavior. With the young and occupational nature of our population, these findings may not generalize to elderly persons or to the wider general population.

Notwithstanding these limitations, extensive sensitivity and additional analyses were conducted to investigate effects of potential bias in this study and in our earlier studies that used the same methodology. These included different adjustments and controls in the analysis and different study inclusion and exclusion criteria, to investigate whether effectiveness estimates could have been biased [18,29]. These analyses showed consistent findings [18, 28, 29, 55, 56].

In conclusion, recent influenza vaccination is associated with a significant reduction in the risk of SARS-CoV-2 infection and COVID-19 severity. The findings support benefits for influenza vaccination that extend beyond protection against influenza infection and associated severe disease.

Funding

The authors are grateful for institutional salary support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for institutional salary support provided by the Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine. Open access funding provided by the Qatar National Library. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors.

CRediT authorship contribution statement

ET, SA, MAA, and AAK co-conceived and co-designed the study, conducted literature review, co-developed the database, and co-wrote the first draft of the article. HC co-designed the study, co-developed the database, performed the statistical analyses, and co-wrote the first draft of the article. LJJA co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript. All authors have read and agreed to the published version of the manuscript.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgments

We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, Qatar Biobank, Sidra Medicine, and Weill Cornell Medicine-Qatar for their diligent efforts and contributions to make this study possible.

Ethics approval and consent to participate

Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards approved this retrospective study with a waiver of informed consent. The research was performed in accordance with relevant guidelines and regulations.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.jiph.2022.12.016.

References

[1] Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, et al. Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season. N Engl J Med 2017;377(6):534–43. PubMed PMID: 28702867. Pubmed Central PMCID: PMC5727917. Epub 2017/08/10.

[2] Pearson ML, Bridges CB, Harper SA. Healthcare infection control practices advisory council, advisory committee on immunization practices. Influenza and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-2):1–16. PubMed PMID: 1648385. Epub 2006/02/25.

[3] Conlon A, Ashur C, Washler L, Eagle KA, Hofmann, Bowman MA. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control 2021;49(8):694–700. PubMed PMID: 33631305. Pubmed Central PMCID: PMC7899024. Epub 2021/02/26.

[4] Fink G, Orlova-Fink N, Schindler T, Grisi S, Ferrer APS, Daubenberger C, et al. Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil. BMJ Evid Based Med 2020. PubMed PMID: 33310766. Pubmed Central PMCID: PMC7735072. Epub 2020/11/15.

[5] Huang K, Lin SW, Sheng WH, Wang CC. Influenza vaccination and the risk of COVID-19 infection and severe illness in older adults in the United States. Sci Rep 2021;11(1):11025. PubMed PMID: 34040014. Pubmed Central PMCID: PMC8155195. Epub 2021/05/25.

[6] Taghioff SM, Slavin BR, Holton T, Singh D. Examining the potential benefits of the influenza vaccine against SARS-CoV-2: a retrospective cohort analysis of 74,754 patients. PLoS One 2021;16(8):e0255541. PubMed PMID: 34343191. Pubmed Central PMCID: PMC8339018 Taghioff, and Dr. Singh have no relevant disclosures. The authors have not received any consulting fees, stock options, re-search funding, capital equipment, or educational grants from TriNetX. Epub 2021/08/04.

[7] Debisanur PA, Gossling KL, Bulot O, Kilic G, Zoodsma M, Liu Z, et al. Induction of trained immunity via influenza vaccination – impact on COVID-19. PLoS Pathog 2021;17(10):e1009926. PubMed PMID: 34695164. Pubmed Central PMCID: PMC8358826. Epub 2021/10/26.

[8] Ragni P, Marino M, Formisano D, Biscaccia E, Scaltriti S, Bedeschi E, et al. Association between exposure to influenza vaccination and COVID-19 diagnosis and outcomes. Vaccin (Basel) 2020;8(4). PubMed PMID: 33198368. Pubmed Central PMCID: PMC771765. Epub 2020/11/18.

[9] Marin-Hernandez D, Schwartz RE, Nixon DF. Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy. J Med Virol 2021;93(1):64–5. PubMed PMID: 34026 201. Pubmed Central PMCID: PMC8155195. Epub 2020/05/25.

[10] Massoudi N, Mohit B. A case-control study of the 2019 influenza vaccine and incidence of COVID-19 among healthcare workers. J Clin Immunol 2021;41(2):324–34. PubMed PMID: 33244671. Pubmed Central PMCID: PMC809338. Epub 2021/01/28.

[11] Pawloski C, Puranik A, Bandi H, Venkatkrishnan AJ, Agarwala V, Kennedy R, et al. Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. Sci Rep 2021;11(1):4741. PubMed PMID: 33637783. Pubmed Central PMCID: PMC7910541. Epub 2021/02/28.

[12] Candellini M, Pignataro G, Torelli E, Gulli A, Nista EC, Petrucci M, et al. Effect of influenza vaccine on COVID-19 mortality: a retrospective study. Intern Emerg Med 2021;16(7):1849–55. PubMed PMID: 33743150. Pubmed Central PMCID: PMC7980752. Epub 2021/03/21.

[13] Seif-Farshad M, Alizadeh M, Khayatzadeh S, Heidari F. The relationship of COVID-19 morbidity and mortality with the history of influenza vaccination. Med Islam Repub Iran 2022;36:122. PubMed PMID: 36447553. Pubmed Central PMCID: PMC9700421. Epub 2022/12/01. eng.

[14] Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in influenza vaccine against SARS-CoV-2: a retrospective cohort analysis of 74,754 patients. PLoS One 2021;16(8):e0255541. PubMed PMID: 34343191. Pubmed Central PMCID: PMC8339018 Taghioff, and Dr. Singh have no relevant disclosures. The authors have not received any consulting fees, stock options, re-search funding, capital equipment, or educational grants from TriNetX. Epub 2021/08/04.

[15] World Health Organization. COVID-19 clinical management: living guidance, https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1; 2021 [accessed May 31, 2021].

[16] World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as a cause of death. Document Number: WHO/HQ/DDDS/DATA/CAT, https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19–20200420-EN.pdf?ua=1; 2021 (Accessed 31 May 2021).

[17] Abu-Raddad LJ, Chenaitelle H, Ayoub HH, Al Kayani Z, Al Khairi A, Al Kuwari E, et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci Rep 2021;11(1):6233. PubMed PMID: 33773535. Pubmed Central PMCID: PMC8737343. Epub 2021/03/20.

[18] Chenaitelle H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med 2021;383(24):e83. PubMed PMID: 34614327. Pubmed Central PMCID: PMC8522799. Epub 2021/10/07.
Abu-Raddad LJ, Chemaitelly H, Assine HM, Benslimane FM, Al Khatib HA, Tang-Kissling E, Hooiveld M, Brytting M, Vilcu AM, de Lange M, Martinez-Baz I, et al. Youb H.H., Tomy M., Chemaitelly H., Altarawneh H.N., Coyle P., Tang P., et al. Chemaitelly H, Assine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, Al- Thani MH, Farag E, Bertollini R, Al Romaihi HE, Abdeen S, Abdelkarim A, et al. Erismis B, Karabela SN, Eksi F, Karander F, Dogan B, Okay F, et al. Annual in Jerjenko A, Chemaitelly H, Youb HH, Alishaq M, Abou-Samra AB, Al Ajmi J, Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Altarawneh HN, Chemaitelly H, Youb HH, Coyle P, Malek JA, Ahmed AA, et al. Youb HH, Chemaitelly H, Seedat S, Makhoul M, Al Kanaani Z, Al, et al. Salem ML, El-Hennawy D. The possible beneficial adjuvant effect of influenza vaccine on the severity of COVID-19. Med Hypotheses 2020;140:109752. PubMed PMID: 32361099. Pubmed Central PMCID: PMC7194943. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819452. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819453. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819454. Pubmed PMID: 34050501. Pubmed Central PMCID: PMC819455. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819456. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819457. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819458. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819459. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819460. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819461. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819462. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819463. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819464. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819465. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819466. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819467. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819468. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819469. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819470. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819471. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819472. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819473. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819474. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819475. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819476. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819477. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819478. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819479. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819480. Pubmed PMID: 34050372. Pubmed Central PMCID: PMC819481.